Feed Articles

Popular asthma drug linked to serious psychological problems

The drug montelukast, known by its brand name Singulair, was considered a revolution in asthma treatment when it was introduced in 1998. It offered an easy alternative to inhalers and was promoted as safe with minimal side effects. However, new scientific findings and thousands of reports of serious mental health problems, including suicides, have cast doubt on its safety.

Montelukast and its original promise

Findings from the FDA and scientists

After analyzing thousands of reports, the U.S. Food and Drug Administration (FDA) added a "black box" warning, the highest level of warning about the drug's potential risks, to montelukast in 2020. This warning highlights possible serious psychological side effects such as depression, suicidal thoughts and actions.

At a scientific conference in Austin, Texas, FDA researchers presented the new lab test results. These showed that montelukast binds to receptors in the brain that regulate mood, impulsivity, sleep and cognitive function. According to the FDA's Jessica Oliphant, these are "significant bindings," with the highest concentrations of the drug found in areas of the brain involved in psychological functions.

Who is most at risk?

Although researchers have not confirmed a direct causal link between the use of the drug and its effects on the psyche, they point out that some cases are alarming. For example, Robert England, whose son committed suicide shortly after being put on montelukast, described how quickly the healthy young man began to behave unusually.

According to FDA statistics, 82 suicides associated with montelukast use have been reported from 1998 to 2019, including at least 31 in children and adolescents under the age of 19. These cases raise questions about the safety of the drug, especially for young patients.

Reactions from pharmaceutical companies

Neither Merck, the original manufacturer of Singulair, nor its offshoot Organon, which now distributes the drug, has yet admitted to any major wrongdoing. Organon has said that the drug's label contains adequate information about its risks and benefits. Meanwhile, however, lawsuits are pending against Merck, which claims that the company knew from initial research about the drug's potential effects on the psyche, but minimized that information.

Disclaimer: You will find a lot of inspiration on Bulios, but stock selection and portfolio construction is up to you, so always do a thorough analysis of your own.

Source: Investing.com, Reuters.

A community member's personal view, not investment advice. Community Guidelines

Follow Bulios on Google News

Be among the first to discover new analyses, news and market moves.

Follow

Recommended articles

Read more

Expensive oil was supposed to sink them; these 3 cruise lines instead report records and expect further growth

Oil this year soared to $138 per barrel, and cruise ships, which burn hundreds of thousands of tons of it annually, were supposed to be the first to suffer. Instead, all three largest cruise operators raised their profit outlooks, yet for a dollar of profit the market pays almost twice as much for…

MC
Milan Charvat
· 5h
Read more
BLACK

Man with Parkinson's stood up and walked away after an injection. The drugmaker's stock still fell 20%

A man with Parkinson's who couldn't get up from a chair walked out through the door on his own after a year of treatment with his own cells. The company behind the treatment raised $140.6 million in its IPO, and three weeks later its stock is 20% cheaper, even though there hasn't been a single…

MC
Milan Charvat
· 10h
Read more
BLACK

Dividends Above 10%? No Problem for These Stocks

A yield of over 15% a year sounds almost unbelievable in the stock market, yet several established US-listed securities are offering just that today. Mortgage REITs and leveraged bond funds earn money from the difference between the yield on mortgages or bonds and the cost of short-term financing,…

KJ
Kryštof Jáně
· 13h

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy